Background. Antimicrobial stewardship programs promote de-escalation: moving from broad to narrow spectrum agents and/or stopping antibiotics as more clinical data return. A standard definition of de-escalation objectively applied to electronic data could provide a means to assess stewardship improvement opportunities.
Methods. We performed a retrospective cohort study of de-escalation events among five hospitals from the Duke Health System and the Duke Antimicrobial Stewardship Outreach Network using 2016 electronic medication administration record data. Antibiotics were ranked into four categories: narrow spectrum (e.g., cefazolin), broad spectrum, extended spectrum, and agents typically targeted for protection (e.g., meropenem). Included patients were cared for on inpatient units, had antibiotic therapy for at least 2 days, and had at least 3 days of hospitalization after starting antibiotics. De-escalation was defined as reduction in either the number of antibiotics or rank measured at two time points: day 1 of initiation of antibiotic therapy and day 5 (or day of discharge if occurring on day 3 or 4). Escalation was an increase in either number or rank of agents. Unchanged was either no change or discordant directions of change in number and rank. For all categories, the outcome was percent among qualifying admissions. Descriptive statistics were used to describe de-escalation among hospitals, unit type, and ICD-10 diagnoses.
Results. Among 39,226 included admissions, de-escalation occurred in 14,138 (36%), escalation in 5,129 (13%), and antibiotics were unchanged in 19,959 (51%) (Figure) . Percent de-escalation was significantly different among hospitals (median 37%, range 31-39%, P < .001). Infectious diagnoses with lower rates of de-escalation included intra-abdominal infection (23%), skin and soft-tissue infection (28%), and ENT/upper respiratory tract infection (19%). Intensive care units had higher rates of both de-escalation and escalation (43% and 16%) when compared with non-ICU wards (35% and 13%, P < .001).
Conclusion. We provided an objective, electronic definition of de-escalation and demonstrated variation among hospitals, units, and diagnoses. This metric may be useful for assessing stewardship opportunities. Background. The role of MRSA nasal surveillance swabs in guiding decisions about need for subsequent vancomycin therapy is unclear. Our objectives were to (1) determine the likelihood that patients with negative MRSA nasal swabs went on to develop MRSA infections during the same hospitalizations to assess if vancomycin therapy could be avoided once the nasal swab result returns negative, (2) assess days of vancomycin that potentially could be avoided, and (3) identify risk factors for having a negative MRSA nasal swab and developing an MRSA infection during the hospital stay.
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The Role of Negative Methicillin-Resistant Staphylococcus aureus
Methods. This retrospective cohort study was conducted at six intensive care units (ICUs) at a tertiary care hospital in Baltimore from December 2013 to June 2015. MRSA nasal swabs are obtained at the time of admission and weekly thereafter for all ICU patients. The negative predictive value (NPV), defined as the ability of a negative MRSA nasal screening test to correctly predict no subsequent MRSA infection during the hospital stay, was calculated, accounting for the 3-day turnaround time of MRSA nasal surveillance swabs. Days of vancomycin therapy started or continued after 3 days from the first negative MRSA nasal swab were determined by chart review. A matched case-control study was performed to identify risk factors for patients with negative MRSA surveillance cultures who subsequently developed MRSA infections.
Results. Of 11,441 MRSA-nasal swab negative patients, the proportion of subsequent incident MRSA infections was 0.2%. Negative MRSA surveillance swabs had an NPV of 99.4% (95% CI 99.1-99.6%). Among 4,091 MRSA-negative patients receiving vancomycin, vancomycin was started or continued after 3 days since the first MRSAnegative nasal swab in 1,434 patients (35%), translating to 7,377 potentially avoidable vancomycin days. The matched case-control analysis did not identify risk factors associated with subsequent MRSA infection.
Conclusion. At our institution with robust infection control practices and low nosocomial MRSA transmission rates, patients with negative MRSA nasal swabs have a very low likelihood of subsequent MRSA infection during hospitalizations. MRSA nasal swabs can provide useful information when determining whether to initiate or stop empiric vancomycin.
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